Form 4: Heron Therapeutics CEO Exercises RSUs, Boosts Stake

Heron Therapeutics CEO Craig Collard acquired 13,797 shares of common stock through the exercise of restricted stock units.

Summary

• Craig A Collard, Chief Executive Officer and Director of Heron Therapeutics, Inc. (HRTX), acquired 13,797 shares of common stock.
• This acquisition occurred on January 19, 2026, through the exercise of restricted stock units (RSUs).
• Following this transaction, Collard directly beneficially owns 536,921 shares of common stock.
• He also continues to hold 110,375 unexercised restricted stock units.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• The restricted stock units vest in 16 equal quarterly installments, commencing one quarter after their grant date of January 19, 2024.

Sentiment

Score: 7

Explanation: The filing indicates a routine exercise of restricted stock units by the CEO, increasing his direct ownership in the company. This is generally viewed positively as it aligns management's interests with shareholders, though it's a scheduled event rather than a discretionary open-market purchase.

Positives

• CEO Craig Collard increased his direct ownership of common stock by 13,797 shares, aligning his interests further with shareholders.
• The exercise of restricted stock units represents a vesting event, indicating the fulfillment of compensation terms and continued commitment from management.

Future Outlook

The remaining 110,375 restricted stock units held by Craig Collard are scheduled to continue vesting in 16 equal quarterly installments, with the vesting period having commenced one quarter after the January 19, 2024 grant date.

Industry Context

This filing reflects a routine insider transaction for a pharmaceutical company, where executive compensation often includes equity awards like restricted stock units that vest over time. Such transactions are common across industries as a mechanism to align executive incentives with long-term company performance.

Stakeholder Impact

• Shareholders: The increase in the CEO's direct stock ownership enhances the alignment of management's financial interests with those of the shareholders.
• Employees: The transaction reflects the execution of standard executive compensation practices, which can be a positive signal regarding the company's commitment to its compensation structure.

Next Steps

• Continued vesting of the remaining 110,375 restricted stock units in 16 equal quarterly installments.

Key Dates

Recommendation

This Form 4 reports a routine, scheduled exercise of restricted stock units by the CEO, which increases his direct ownership in the company. While this aligns management's interests with shareholders, it does not represent a discretionary open-market purchase or provide new fundamental information about the company's operational or financial performance. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Heron Therapeutics, HRTX, Craig Collard, CEO, Director, SEC Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, RSU Exercise, Beneficial Ownership